Pharming Group N.V. - ADR Forecast, price target & analysts
Pharming Group N.V. - ADR Target price 2024 - Analyst rating & recommendation
Pharming Group N.V. - ADR Classifications & Recommendation:
Pharming Group N.V. - ADR Target price
| Target price | $27.79 |
| Course | $8.35 |
| Price potential |
232.78%
register free of charge
|
| Number of estimates | 4 |
|
4 Analysts have issued a price target Pharming Group N.V. - ADR 2025 .
The average Pharming Group N.V. - ADR target price is $27.79.
This is
232.78%
register free of charge
$40.00
379.04%
register free of charge
$16.26
94.75%
register free of charge
|
|
| A rating was issued by 5 analysts: 5 Analysts recommend Pharming Group N.V. - ADR to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the Pharming Group N.V. - ADR share has an average upside potential 2025 of
232.78%
register free of charge
|
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Million $ | 245.70 | 287.61 |
| 19.43% | 17.06% | |
| EBITDA margin | -4.49% | 2.61% |
| 173.42% | 158.09% | |
| Net margin | -4.37% | 2.33% |
| 163.80% | 153.32% |
3 Analysts have issued a sales forecast Pharming Group N.V. - ADR 2024 . The average Pharming Group N.V. - ADR sales estimate is
This results in the following potential growth figures:
2 Analysts have issued an Pharming Group N.V. - ADR EBITDA forecast 2024. The average Pharming Group N.V. - ADR EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share $ | -0.16 | 0.10 |
| 176.19% | 162.50% | |
| P/E ratio | 83.50 | |
| EV/Sales | 1.83 |
Based on analysts' sales estimates for 2024, the Pharming Group N.V. - ADR share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
Pharming Group N.V. - ADR...
Discover more stocks with a high price target
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.
